Eli Lilly Next-Gen Weight Loss Drug Faces Scrutiny Over Heart Event Efficacy

By Elaine Chen · STAT News · 2026-07-23

STAT News reports that recent Phase 3 clinical data for Eli Lilly’s retatrutide showed massive weight reduction but failed to prove a decrease in heart attacks or strokes compared to a placebo. While participants on the highest dose lost nearly 23% of their body weight, the trial

STAT News reports that recent Phase 3 clinical data for Eli Lilly’s retatrutide showed massive weight reduction but failed to prove a decrease in heart attacks or strokes compared to a placebo. While participants on the highest dose lost nearly 23% of their body weight, the trial